Dimensional Fund Advisors
PSTX

Dimensional Fund Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Dimensional Fund Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-463,683
Closed -$4.45M – 3391
2024
Q4 		$4.45M Sell
463,683
-99,452
-18% -$519K ﹤0.01% 2567
2024
Q3 		$1.61M Sell
563,135
-36,677
-6% -$114K ﹤0.01% 2829
2024
Q2 		$1.75M Buy
599,812
+9,672
+2% +$26.5K ﹤0.01% 2795
2024
Q1 		$1.88M Buy
590,140
+102,939
+21% +$343K ﹤0.01% 2806
2023
Q4 		$1.64M Buy
487,201
+100,939
+26% +$260K ﹤0.01% 2826
2023
Q3 		$920K Sell
386,262
-314,264
-45% -$659K ﹤0.01% 2946
2023
Q2 		$1.23M Sell
700,526
-53,599
-7% -$137K ﹤0.01% 2890
2023
Q1 		$2.32M Buy
754,125
+477,706
+173% +$2.86M ﹤0.01% 2713
2022
Q4 		$1.47K Buy
276,419
+155,476
+129% +$711K ﹤0.01% 2809
2022
Q3 		$428K Sell
120,943
-24,089
-17% -$79.7K ﹤0.01% 3076
2022
Q2 		$374K Buy
145,032
+465
+0.3% +$1.29K ﹤0.01% 3131
2022
Q1 		$648K Buy
144,567
+47,233
+49% +$213K ﹤0.01% 3093
2021
Q4 		$663K Buy
+97,334
New +$663K ﹤0.01% 3111

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Dimensional Fund Advisors's PSTX Position: Q1 2025 in Review

Dimensional Fund Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 463,683 shares — an estimated $4.45M sold.

Dimensional Fund Advisors first reported a position in PSTX in Q4 2021 and held it in 13 quarters. The position peaked at $4.45M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Dimensional Fund Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 463,683 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $4.45M.
  • Dimensional Fund Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 13 quarters.
  • Dimensional Fund Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $4.45M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Dimensional Fund Advisors's 13F filing for Q1 2025, filed 13 May 2025.